doc. MUDr. Daniela Žáčková, Ph.D.
Associate professor, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 2838, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 222
2024
-
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data
Cancer Medicine, year: 2024, volume: 13, edition: 17, DOI
-
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
American Journal of Hematology, year: 2024, volume: 99, edition: 4, DOI
-
Expression of the immune checkpoint inhibitors on gamma-delta T cells in chronic myeloid leukemia patients during TKI therapy
Year: 2024, type: Appeared in Conference without Proceedings
-
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
Leukemia, year: 2024, volume: 38, edition: 8, DOI
-
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
Leukemia, year: 2024, volume: 38, edition: 5, DOI
-
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
Blood advances, year: 2024, volume: 8, edition: 10, DOI
-
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Leukemia, year: 2024, volume: 38, edition: 2, DOI
-
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Leukemia, year: 2024, volume: 38, edition: 4, DOI
2023
-
Analysis of factors influencing the decision to stop TKI treatment in CML patients in deep molecular response
Year: 2023, type: Conference abstract
-
Asciminib - nová možnost v léčbě CML
Farmakoterapie, year: 2023, volume: 19, edition: 3